Prominent publications by Brian J Reid

KOL Index score: 17724

The value of endoscopic surveillance biopsy for dysplasia and carcinoma in patients with Barrett's esophagus is controversial. One reason is that the available histologic criteria are not adequate to separate patients with lesser degrees of dysplasia or predysplastic changes who are at increased risk for carcinoma and therefore require more frequent surveillance from those patients who are not at increased risk. We used flow cytometry and histology to evaluate 317 biopsy specimens from ...

Also Ranks for: Flow Cytometry |  dysplasia patients |  carcinoma barretts esophagus |  frequent surveillance |  biopsy specimens
KOL Index score: 17186

BACKGROUND: Abnormalities involving the p16 (also known as cyclin-dependent kinase N2 [CDKN2], p16 [INK4a], or MTS1) and p53 (also known as TP53) tumor suppressor genes are highly prevalent in esophageal adenocarcinomas. Loss of heterozygosity (LOH) at 9p21 and 17p13 chromosomes (locations for p16 and p53 genes, respectively) is frequently observed in the premalignant condition, Barrett's esophagus. We studied extensively the distribution and heterogeneity of LOH at 9p and 17p ...

Also Ranks for: Chromosomes 9p |  clonal expansion |  loss heterozygosity |  premalignant esophageal |  highgrade dysplasia
KOL Index score: 16798

The tumor suppressor gene APC was recently identified, and the cDNA was cloned from chromosome 5q21. Point mutations affecting APC are seen in the hereditary syndrome familial adenomatous polyposis, and point mutations in APC and a closely linked gene, MCC, as well as loss of heterozygosity involving chromosome 5q have been reported in sporadic colon cancer. To our knowledge, loss of heterozygosity involving APC or MCC or both has not yet been described in any other human cancer besides ...

Also Ranks for: Loss Heterozygosity |  apc mcc |  esophageal cancers |  chromosome 5q |  molecular dna
KOL Index score: 16433

OBJECTIVES: Most patients with Barrett's esophagus do not progress to cancer, but those who do seem to have markedly increased survival when cancers are detected at an early stage. Most surveillance programs are based on histological assessment of dysplasia, but dysplasia is subject to observer variation and transient diagnoses of dysplasia increase the cost of medical care. We have previously validated flow cytometric increased 4N fractions and aneuploidy as predictors of progression to ...

Also Ranks for: Progression Barretts Esophagus |  human pair |  grade dysplasia patients |  p53 loh |  esophageal adenocarcinoma
KOL Index score: 15093

Both 17p and 5q allelic losses appear to be involved in the pathogenesis or progression of many human solid tumors. In colon carcinogenesis, there is strong evidence that the targets of the 17p and 5q allelic losses are TP53, the gene encoding p53, and APC, respectively. It is widely accepted that 5q allelic losses precede 17p allelic losses in the progression to colonic carcinoma. The data, however, supporting this proposed order are largely based on the prevalence of 17p and 5q allelic ...

Also Ranks for: Allelic Losses |  chromosomes human |  apc genes |  aneuploid populations |  barrett esophagus
KOL Index score: 14127

OBJECTIVE: Barrett's esophagus develops in 5-20% of patients with gastroesophageal reflux disease and predisposes to esophageal adenocarcinoma. The value of endoscopic biopsy surveillance is questioned because most patients do not develop cancer. Furthermore, observer variation in histological diagnosis makes validation of surveillance guidelines difficult because varying histological interpretations may lead to different estimated rates of progression. Thus, objective biomarkers need to ...

Also Ranks for: Progression Cancer |  flow cytometry |  baseline histology |  5 patients |  barretts esophagus
KOL Index score: 14123

BACKGROUND: Somatic genetic CDKN2A, TP53, and DNA content abnormalities are common in many human cancers and their precursors, including esophageal adenocarcinoma (EA) and Barrett's esophagus (BE), conditions for which aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have been proposed as possible chemopreventive agents; however, little is known about the ability of a biomarker panel to predict progression to cancer nor how NSAID use may modulate progression. We aimed to ...

Also Ranks for: Esophageal Adenocarcinoma |  dna content |  loh chromosomes human |  nsaids modulate |  nsaid users
KOL Index score: 13914

PURPOSE: Leukocyte telomere length has gained attention as a marker of oxidative damage and age-related diseases, including cancer. We hypothesize that leukocyte telomere length might be able to predict future risk of cancer and examined this in a cohort of patients with Barrett's esophagus, who are at increased risk of esophageal adenocarcinoma and thus were enrolled in a long-term cancer surveillance program.

PATIENTS AND METHODS: In this prospective study, telomere length was measured ...

Also Ranks for: Leukocyte Telomere Length |  cancer risk |  esophageal adenocarcinoma |  barretts esophagus |  patients barrett
KOL Index score: 13815

Barrett's esophagus is a condition in which the normal stratified squamous epithelium is replaced by metaplastic columnar epithelium that predisposes to the development of esophageal adenocarcinoma. Neoplastic progression in Barrett's esophagus occurs by a multistep process associated with genomic instability and the development of aneuploid cell populations. p53 protein overexpression and allelic deletions on chromosome 17p have been shown to be present in some Barrett's ...

Also Ranks for: P53 Protein |  barretts esophagus |  neoplastic progression |  flow cytometry |  adenocarcinoma patients
KOL Index score: 13497

BACKGROUND: The increased risk for esophageal adenocarcinoma associated with long-segment (> or =3 cm) Barrett esophagus is well recognized. Recent studies suggest that short-segment (<3 cm) Barrett esophagus is substantially more common; however, the risk for neoplastic progression in patients with this disorder is largely unknown.

OBJECTIVE: To examine the relation between segment length and risk for aneuploidy and esophageal adenocarcinoma in patients with Barrett esophagus.


Also Ranks for: Segment Length |  neoplastic progression |  barrett esophagus |  esophageal adenocarcinoma patients |  highgrade dysplasia
KOL Index score: 12913

BACKGROUND/AIMS: Allelic losses of chromosome 17p and overexpression of p53 protein have been reported in Barrett's adenocarcinomas. This study aimed to determine the stage in which p53 mutations arise in neoplastic progression in Barrett's esophagus and their relationship to the clonal evolution of cancer.

METHODS: Fourteen patients with high-grade dysplasia, adenocarcinoma, or both arising in Barrett's esophagus were evaluated. Flow cytometric cell sorting was used to obtain purified ...

Also Ranks for: P53 Mutations |  grade dysplasia |  barrett esophagus |  cell populations |  neoplastic progression
KOL Index score: 12150

There is debate in the literature over the relative importance of genetic instability and clonal expansion during progression to cancer. Barrett's esophagus is a uniquely suited model to investigate neoplastic progression prospectively because periodic endoscopic biopsy surveillance is recommended for early detection of esophageal adenocarcinoma. We hypothesized that expansion of clones with genetic instability would predict progression to esophageal adenocarcinoma. We measured p16 ...

Also Ranks for: Genetic Instability |  esophageal adenocarcinoma |  clonal expansion |  loss heterozygosity |  progression cancer
KOL Index score: 12138

It has been hypothesized that neoplastic progression develops as a consequence of an acquired genetic instability and the subsequent evolution of clonal populations with accumulated genetic errors1. Accordingly, human cancers and some premalignant lesions contain multiple genetic abnormalities not present in the normal tissues from which the neoplasms arose2,3. Barrett oesophagus (BE) is a premalignant condition which predisposes to oesophageal adenocarcinoma (EA) that can be biopsied ...

Also Ranks for: Barrett Oesophagus |  neoplastic progression |  human pair |  cell lineage |  heterozygosity models

Key People For Esophageal Adenocarcinoma

Top KOLs in the world
Jesper *********
esophageal adenocarcinoma gastric cancer antireflux surgery
Thomas ******* *******
esophageal adenocarcinoma lung cancer united states
Nicholas ***** *******
eosinophilic esophagitis esophageal adenocarcinoma barrett esophagus
Stuart *** ********
barrett esophagus eosinophilic esophagitis intestinal metaplasia
Rebecca * **********
oesophageal adenocarcinoma barretts oesophagus gastric cancer
Brian * ****
esophageal adenocarcinoma neoplastic progression barretts esophagus

Brian J Reid:Expert Impact

Concepts for whichBrian J Reidhas direct influence:Esophageal adenocarcinoma,  Barretts esophagus,  Neoplastic progression,  Barrett esophagus,  Risk esophageal adenocarcinoma,  Allelic loss,  Oesophageal adenocarcinoma,  P53 protein overexpression.

Brian J Reid:KOL impact

Concepts related to the work of other authors for whichfor which Brian J Reid has influence:Esophageal adenocarcinoma,  Barrett esophagus,  Breast cancer,  Intestinal metaplasia,  Early detection,  Cell cycle,  Grade dysplasia.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Fred Hutchinson Cancer Research Center | Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA | Department of Genome Sciences, University of Washington, Seattle, WA, USA | Divisions of Human Biology and Public Health Sc